FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Kasamon, Yvette L., de Claro, R. Angelo, Wang, Yaping, Shen, Yuan Li, Farrell, Ann T., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Regulatory Issues: FDA
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423515/
https://ncbi.nlm.nih.gov/pubmed/28438889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares